Precision Psychiatry & Genomic Medicine
Traditional psychiatry often relies on a "one-size-fits-all" approach to medication, which can lead to months of frustrating trial and error. At our practice, we utilize Genomic Medicine to bypass this uncertainty. By analyzing your unique genetic blueprint, we identify how your body metabolizes specific medications and how your brain’s receptors are likely to respond to different therapeutic classes.
A Research-Driven Approach This isn't just clinical implementation; it is a direct extension of my academic career. With over two decades of research in neuroscience and behavioral genomics, I have authored over 170 peer-reviewed publications investigating the genetic architecture of psychiatric disorders. My work—published in journals such as JAMA Psychiatry, Nature Aging, and Pharmacogenomics—focuses on identifying the specific serotonin and dopamine pathway polymorphisms that dictate treatment response.
In this practice, we translate that high-level molecular research into a personalized clinical roadmap. We use advanced pharmacogenomic testing to:
Predict Treatment Response: Identifying which medications are biologically most compatible with your system.
Minimize Side Effects: Avoiding medications that your body may metabolize too slowly or too quickly.
Optimize Dosing: Using genomic data to fine-tune dosages for maximum efficacy and safety.
Moving Beyond "Trial and Error" Through Molecular Insight
Clinical Research & Selected Publications
Psychiatric Genetics in Clinical Practice: Essential Knowledge for Mental Health Professionals. American Journal of Psychiatry, 2025 > The Insight: As a lead contributor to these clinical guidelines, I help define the global standards for how genetics should be integrated into psychiatric care. This ensure our practice utilizes the most current and ethically sound genomic protocols available to the medical community.
Multivariate genome-wide analysis of aging-related traits identifies novel loci and new drug targets for healthy aging. Nature Aging, 2023 > The Insight: This high-impact study identifies specific biological pathways that govern how we age. We use these "aging-related loci" to inform our longevity protocols, aiming to optimize brain health and cognitive resilience throughout the lifespan.
Multi-omic underpinnings of epigenetic aging and human longevity. Nature Communications, 2023 > The Insight: By analyzing the "epigenetic clock"—the chemical markers on your DNA that track biological age—this research explores why some individuals age more successfully than others. It provides the molecular basis for our precision approach to longevity and "healthspan."
Focal adhesion is associated with lithium response in bipolar disorder: evidence from a network-based multi-omics analysis. Molecular Psychiatry, 2024 > The Insight: This paper maps the cellular networks that determine how a patient responds to mood stabilizers like Lithium. This "multi-omic" perspective allows us to understand treatment response at a deeper level, moving beyond clinical observation to molecular certainty.
Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis. JAMA Psychiatry. 2021> The Insight: Utilizing advanced statistical genetics, this study clarifies the causal relationships between medication use and mental health outcomes. This research reinforces our commitment to data-driven safety and precision when managing complex medication regimens.